Takashi Kawakami

Takashi Kawakami

Auto-generated profile, based on publicly available information

Takashi Kawakami

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
TKTakashi Kawakami
Takashi Kawakami
HMHiromi Matsubara
Hiromi Matsubara
TSToshiro Shinke
Toshiro Shinke
KAKohtaro Abe
Kohtaro Abe
SKShun Kohsaka
Shun Kohsaka
KFKeiichi Fukuda
Keiichi Fukuda

1 July 2018 in Respiratory Investigation
Verified
Journal Article
Closed access
NTNobuhiro Tanabe
Nobuhiro Tanabe
TKTakashi Kawakami
Takashi Kawakami
TSToru Satoh
Toru Satoh
HMHiromi Matsubara
Hiromi Matsubara
NNNorifumi Nakanishi
Norifumi Nakanishi
KTKoichiro Tatsumi
Koichiro Tatsumi

1 October 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
TITaku Inohara
Taku Inohara
TKTakashi Kawakami
Takashi Kawakami
MKMasaharu Kataoka
Masaharu Kataoka
MYMasanori Yamamoto
Masanori Yamamoto
MKMai Kimura
Mai Kimura
KFKeiichi Fukuda
Keiichi Fukuda

1 January 2016 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
TKTakashi Kawakami
Takashi Kawakami
MKMasaharu Kataoka
Masaharu Kataoka
TATakahide Arai
Takahide Arai
RYRyo Yanagisawa
Ryo Yanagisawa
YMYuichiro Maekawa
Yuichiro Maekawa
KFKeiichi Fukuda
Keiichi Fukuda

4 April 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
MKMai Kimura
Mai Kimura
MKMasaharu Kataoka
Masaharu Kataoka
TKTakashi Kawakami
Takashi Kawakami
TITaku Inohara
Taku Inohara
MTMakoto Takei
Makoto Takei
KFKeiichi Fukuda
Keiichi Fukuda

6 February 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
TKTakashi Kawakami
Takashi Kawakami
HMHiromi Matsubara
Hiromi Matsubara
KAKohtaro Abe
Kohtaro Abe
MKMasaharu Kataoka
Masaharu Kataoka
SKShun Kohsaka
Shun Kohsaka
KFKeiichi Fukuda
Keiichi Fukuda
Introduction Management of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remains a clinical challenge. Currently, medical treatment involving pulmonary vasodilators (such as soluble guanylate-cyclase stimulators) is recommended, primarily for ameliorating symptoms. More recently, balloon pulmonary angioplasty (BPA) has been developed as alternative treatment for inoperable CTEPH. This study aimed to compare the efficacy and safety of BPA and riociguat (a soluble guanylate-cyclase stimulator) as treatments for inoperable CTEPH. Methods and analysis This study is a multicentre randomised controlled trial. Subjects with inoperable CTEPH were randomised (1:1) into either a BPA or riociguat group, and observed for 12 months after initiation of treatment. The primary endpoint will be the change in mean pulmonary arterial pressure from baseline to 12 months after initiation of treatment. For primary analysis, we will estimate the least square means difference and 95% CI for the change of pulmonary arterial pressure between the groups at 12 months using the analysis of covariance adjusted for allocation factors. Ethics and dissemination This study and its protocols were approved by the institutional review board of Keio University School of Medicine and each participating institution. Written informed consent was obtained from all participants. Results will be disseminated at medical conferences and in journal publications. Trial registration number University Hospital Medical Information Network Clinical Trial Registry (UMIN000019549); Pre-results.